Guidance for Industry Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval - US Department of Health and Human Services; Food and Drug Administration Center for Drug Evaluation and Research (2014)
last access: 28.02.2018